Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak pęcherza moczowego (określony jako wysoki stopień złośliwości, powracający po leczeniu).
- •Wszystkie widoczne guzy o charakterze brodawkowatym usunięte w ciągu ostatnich 90 dni przed rozpoczęciem badania.
- •Jeśli guz nie został usunięty przez urologa prowadzącego leczenie, konieczne jest badanie wziernikiem pęcherza w ciągu ostatnich 45 dni.
- •Pacjenci z guzem T1 wysokiego stopnia muszą przejść ponowne badanie w ciągu 90 dni przed rozpoczęciem badania.
- •Rak pęcherza, który powrócił w ciągu 24 miesięcy od ostatniego leczenia BCG.
✗ Disqualifies
- •Obecność raka z komponentem neuroendokrynnym (np. drobnokomórkowego).
- •Czysty rak płaskonabłonkowy lub czysty gruczolakorak bez komponentu nabłonka przejściowego.
- •Nieleczony rak pęcherza moczowego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (58)
University of Alabama at Birmingham Cancer Center
Birmingham, United States
Fairbanks Memorial Hospital
Fairbanks, United States
Banner MD Anderson Cancer Center
Gilbert, United States
Mayo Clinic Hospital in Arizona
Phoenix, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
Sibley Memorial Hospital
Washington D.C., United States
UF Health Cancer Institute - Gainesville
Gainesville, United States
Mayo Clinic in Florida
Jacksonville, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Northwestern University
Chicago, United States
University of Illinois
Chicago, United States
Loyola University Medical Center
Maywood, United States
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
Melrose Park, United States
IU Health West Hospital
Avon, United States
IU Health North Hospital
Carmel, United States
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, United States
IU Health Methodist Hospital
Indianapolis, United States
Mary Bird Perkins Cancer Center - Metairie
Metairie, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
FMH James M Stockman Cancer Institute
Frederick, United States
Brigham and Women's Hospital
Boston, United States
Lahey Clinic
Burlington, United States
Lahey Clinic Peabody
Peabody, United States
Mayo Clinic in Rochester
Rochester, United States
Community Hospital of Anaconda
Anaconda, United States
Billings Clinic Cancer Center
Billings, United States
Bozeman Health Deaconess Hospital
Bozeman, United States
Benefis Sletten Cancer Institute
Great Falls, United States
Great Falls Clinic
Great Falls, United States
Hi-Line Sletten Cancer Center
Havre, United States
Benefis Helena Specialty Center
Helena, United States
Logan Health Medical Center
Kalispell, United States
Community Medical Center
Missoula, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, United States
Hackensack University Medical Center
Hackensack, United States
Memorial Sloan Kettering Monmouth
Middletown, United States
Memorial Sloan Kettering Bergen
Montvale, United States
Roswell Park Cancer Institute
Buffalo, United States
Memorial Sloan Kettering Commack
Commack, United States
Memorial Sloan Kettering Westchester
Harrison, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Memorial Sloan Kettering Nassau
Uniondale, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Geisinger Medical Center
Danville, United States
Geisinger Cancer Center Dickson City
Dickson City, United States
Geisinger Medical Oncology-Lewisburg
Lewisburg, United States
Fox Chase Cancer Center
Philadelphia, United States
Fox Chase Cancer Center-Rockledge
Rockledge, United States
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, United States
Ralph H Johnson VA Medical Center
Charleston, United States
Medical University of South Carolina
Charleston, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Memorial Hospital of Laramie County
Cheyenne, United States
Billings Clinic-Cody
Cody, United States
Trial contact
Aishwarya Vijendran
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.